These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1970386)

  • 1. Cushing syndrome and medroxyprogesterone acetate.
    Donckier JE; Michel LA; Buysschaert M
    Lancet; 1990 May; 335(8697):1094. PubMed ID: 1970386
    [No Abstract]   [Full Text] [Related]  

  • 2. Cushing's syndrome and medroxyprogesterone acetate.
    Grenfell A; Rudenski A; Watts M; Wiltshire C; Day JL; Gray IP
    Lancet; 1990 Jul; 336(8709):256. PubMed ID: 1973810
    [No Abstract]   [Full Text] [Related]  

  • 3. Cushing's syndrome induced by medroxyprogesterone.
    Merrin PK; Alexander WD
    BMJ; 1990 Aug; 301(6747):345. PubMed ID: 2144198
    [No Abstract]   [Full Text] [Related]  

  • 4. The Cushing syndrome induced by medroxyprogesterone acetate.
    Siminoski K; Goss P; Drucker DJ
    Ann Intern Med; 1989 Nov; 111(9):758-60. PubMed ID: 2552887
    [No Abstract]   [Full Text] [Related]  

  • 5. Medroxyprogesterone induced Cushing's syndrome.
    Learoyd D; McElduff A
    Aust N Z J Med; 1990 Dec; 20(6):824-5. PubMed ID: 1963297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prescription of medroxyprogesterone acetate to a patient with pedophilia, resulting in Cushing's syndrome and adrenal insufficiency.
    Krueger RB; Hembree W; Hill M
    Sex Abuse; 2006 Apr; 18(2):227-8. PubMed ID: 16868842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medroxyprogesterone acetate-induced secondary adrenal insufficiency.
    Dux S; Bishara J; Marom D; Blum I; Pitlik S
    Ann Pharmacother; 1998 Jan; 32(1):134. PubMed ID: 9475840
    [No Abstract]   [Full Text] [Related]  

  • 8. Adrenal failure in patients with breast carcinoma after long-term treatment of cyclic alternating oestrogen progesterone.
    Hug V; Kau S; Hortobagyi GN; Jones L
    Br J Cancer; 1991 Mar; 63(3):454-6. PubMed ID: 1825919
    [No Abstract]   [Full Text] [Related]  

  • 9. Oral plus intramuscular medroxyprogesterone acetate (high dose Farlutal) in advanced breast cancer.
    Ngelangel CA; Jimenez MV; Villalon AH; Agustin BM
    Southeast Asian J Trop Med Public Health; 1985 Dec; 16(4):634-7. PubMed ID: 2940689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of adrenal suppression by high-dose medroxyprogesterone acetate in breast cancer patients.
    van Veelen H; Willemse PH; Sleijfer DT; van der Ploeg E; Sluiter WJ; Doorenbos H
    Cancer Chemother Pharmacol; 1985; 15(2):167-70. PubMed ID: 3160504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medroxyprogesterone acetate induced Cushing's syndrome.
    Shotliff K; Nussey SS
    Br J Clin Pharmacol; 1997 Sep; 44(3):304. PubMed ID: 9296330
    [No Abstract]   [Full Text] [Related]  

  • 12. Cushing's syndrome with adrenal suppression and masked hyperandrogenism by high-dose medroxyprogesterone acetate for treatment of endometrial cancer in a young woman with polycystic ovarian syndrome.
    Seo Y; Jeong EG; Kim ES
    Endocrine; 2015 Nov; 50(2):519-21. PubMed ID: 26298265
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety of DMPA.
    Szareswki A; Guillebaud J
    Lancet; 1991 Nov; 338(8775):1157-8. PubMed ID: 1682586
    [No Abstract]   [Full Text] [Related]  

  • 14. Cushing's syndrome and hypothalamic-pituitary adrenal axis suppression induced by medroxyprogesterone acetate.
    Malik KJ; Wakelin K; Dean S; Cove DH; Wood PJ
    Ann Clin Biochem; 1996 May; 33 ( Pt 3)():187-9. PubMed ID: 8791979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Adjuvant hormone therapy in endometrial carcinoma: medroxyprogesterone acetate versus tamoxifen-medroxyprogesterone acetate sequential therapy].
    Vavra N; Salzer H; Sevelda P; Breitenecker G; Czerwenka K; Kucera H
    Gynakol Rundsch; 1990; 30(3):133-43. PubMed ID: 2147161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medroxyprogesterone acetate at very high doses in postmenopausal advanced breast cancer patients.
    Pannuti F; Longhi A; Martoni A; Piana E; Baroni M
    Chemioterapia; 1987 Dec; 6(6):396-8. PubMed ID: 2963702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Gestagen therapy of breast cancer. Effect of high doses on the blood coagulation system].
    Schenk H; Fereberger W
    MMW Munch Med Wochenschr; 1983 Oct; 125(40):875-6. PubMed ID: 6226871
    [No Abstract]   [Full Text] [Related]  

  • 18. [Fluticasone-ritonavir: a drug-drug interaction causing iatrogenic Cushing's syndrome and adrenal insufficiency].
    Rousseau C; Dolz M
    Med Mal Infect; 2014 Oct; 44(10):483-4. PubMed ID: 25282607
    [No Abstract]   [Full Text] [Related]  

  • 19. Cushing syndrome with secondary adrenal insufficiency from concomitant therapy with ritonavir and fluticasone.
    Johnson SR; Marion AA; Vrchoticky T; Emmanuel PJ; Lujan-Zilbermann J
    J Pediatr; 2006 Mar; 148(3):386-8. PubMed ID: 16615973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of iatrogenic Cushing syndrome and apparent mineralocorticoid excess presenting with accelerated hypertension and proteinuria.
    Kong WY; Leedman P; Irish A
    Intern Med J; 2014 Sep; 44(9):932-4. PubMed ID: 25201428
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.